age
Item
6-16 years
boolean
C0001779 (UMLS CUI [1])
asthma
Item
asthma: physician diagnosed asthma, mathacholine pc20<16 mg/ml, treatment with a stable dose of daily inhaled corticosteroid equivalent to 200 micrograms/day of fluticasone or greater for 8 weeks or longer
boolean
C0004096 (UMLS CUI [1])
C0040223 (UMLS CUI [2])
C2065041 (UMLS CUI [3])
C0430567 (UMLS CUI [4])
poor asthma control
Item
poor asthma control: use of beta-agonist for asthma symptoms twice/week or more, nocturnal awakening with asthma symptoms more than once per week, 2 or more emergency department, unscheduled physician visit, prednisone course, or hospitalizations for asthma in the past 12 months, score of 1.5 or greater on the juniper scale of recent asthma control
boolean
C0004096 (UMLS CUI [1,1])
C2700379 (UMLS CUI [1,2])
C2587213 (UMLS CUI [1,3])
C4039704 (UMLS CUI [2])
C2065041 (UMLS CUI [3,1])
C0583237 (UMLS CUI [3,2])
C0019993 (UMLS CUI [4])
gerd symptom
Item
absence of gerd symptoms: no symptoms clearly attributed to ger at the time of enrollment.
boolean
C2367776 (UMLS CUI [1])
prior surgery
Item
surgery: previous anti-reflux or peptic ulcer surgery, previous tracheo-esophageal fistula repair
boolean
C0744961 (UMLS CUI [1])
C0399651 (UMLS CUI [2])
C0749751 (UMLS CUI [3])
C0472916 (UMLS CUI [4])
fev1
Item
pulmonary function:fev1 <60% predicted normal as measured immediately before methacholine bronchoprovocation. methacholine bronchoprovocation limited to participants with an fev1 >70% of predicted in accordance with fda indication
boolean
C0748133 (UMLS CUI [1])
C0430567 (UMLS CUI [2])
comorbidity
Item
other major chronic illnesses: any major chronic illness including but not limited to non-skin cancer, cystic fibrosis, bronchiectasis, myelomeningocele, sickle cell anemia, endocrine disease, congenital heart disease, congestive heart failure, stroke, severe hypertension, insulin-dependent diabetes mellitus, renal failure, liver disorders, immunodeficiency states, significant neurodevelopmental delay or behavioral disorders or other conditions that would interfere with participation in the study.
boolean
C0009488 (UMLS CUI [1])
medication use
Item
medication use: anti-reflux medication (proton pump inhibitors, h2 blockers, bethanecol, metaclopromide) within 1 month; theophylline preparations, azoles, anti-coagulants, insulin, digitalis, any investigative drug within 2 months.
boolean
C0746470 (UMLS CUI [1])
C0358591 (UMLS CUI [2])
C0019593 (UMLS CUI [3])
C0053526 (UMLS CUI [4])
C0025853 (UMLS CUI [5])
C0039771 (UMLS CUI [6])
C0004504 (UMLS CUI [7])
C0003280 (UMLS CUI [8])
C0021641 (UMLS CUI [9])
C0304520 (UMLS CUI [10])
C0013230 (UMLS CUI [11])
drug allergy
Item
drug allergy: previous adverse effects from lansoprazole, other proton pump inhibitors or methacholine challenge.
boolean
C0020517 (UMLS CUI [1,1])
C0050940 (UMLS CUI [1,2])
C0020517 (UMLS CUI [2,1])
C0358591 (UMLS CUI [2,2])
C0020517 (UMLS CUI [3,1])
C0430567 (UMLS CUI [3,2])
non-adherence
Item
non-adherence: inability or unwillingness of the legal guardian to provide consent or inability or unwillingness of the child to provide assent. inability to swallow study medication. inability to perform baseline measurements. less than 80% completion of screening period diaries. inability to contact by telephone. intention to move out of the areqa within 6 months. no pregnancy.
boolean
C1321605 (UMLS CUI [1])
C0021430 (UMLS CUI [2])